Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6721688 | 0.99 | CSNK2A1 (0.37) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4792051 | 0.92 | CSNK2A1 (0.36) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4791595 | 0.91 | CSNK2A1 (0.37) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4793436 | 0.88 | KDM4E (0.35) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4790972 | 0.86 | CSNK2A1 (0.38) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL5338446 | 0.86 | CSNK2A1 (0.34) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4791625 | 0.84 | TLR7 (0.32) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4793073 | 0.84 | TLR7 (0.39) | TLR7 | |
| SCHEMBL6725903 | 0.83 | TLR7 (0.47) | TLR7 | |
| SCHEMBL4308202 | 0.83 | TLR7 (0.41) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019076-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | claimed |
| US-20040019076-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019076-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | IRF3, EIF2AK2, MYD88 | CSNK2A1 1056/4885PIM1 40/4885CSNK2A2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.